Lilly(US:LLY) 智通财经网·2025-11-10 01:40Core Insights - Eli Lilly (LLY.US) announced a global research and licensing agreement with SanegeneBio worth up to $1.2 billion to jointly develop and commercialize RNAi therapies for metabolic diseases [1] - The agreement includes upfront payments and equity investments from Eli Lilly, which will also take over preclinical research, clinical development, and commercialization of RNAi molecules discovered by SanegeneBio [1] - SanegeneBio is eligible for up to $1.2 billion in milestone payments related to discovery, development, regulatory, and commercialization, along with tiered royalties on future product sales [1] Group 1 - RNAi drugs are a new class of therapies that work by "silencing" messenger RNA molecules that encode disease-related proteins [1] - The collaboration will leverage SanegeneBio's proprietary LEAD™ platform to advance RNAi candidates targeting metabolic diseases [1] Group 2 - The LEAD™ (Ligand and Enhancer Assisted Delivery) platform is a tissue-selective delivery technology developed by SanegeneBio, enabling efficient and specific delivery of RNAi drugs to extrahepatic tissues and cells [2] - This platform has the potential to develop breakthrough therapies for metabolic diseases that require only biannual subcutaneous administration [2] - SanegeneBio will be responsible for screening and identifying optimal RNAi active molecules based on the LEAD™ platform, while Eli Lilly will handle subsequent IND application research, clinical development, and commercialization [2]